STOKE THERAPEUTICS INC
STOKNASDAQTrading Snapshot
- Day Range
- $32.87 – $33.67
- 52-Week Range
- $12.86 – $40.22
- Volume
- $5.10B
- Avg Volume
- $6.27B
- Shares Outstanding
- 62.3M
- Next Earnings
- Sep 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $184M
- Last Q Revenue
- $9M
- P/E Ratio
- —
- P/S Ratio
- 75.1x
- EPS (TTM)
- $-3.36
- Dividend Yield
- —
Why Investors Own STOK
- ✓High-growth profile — revenue up -1.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About STOKE THERAPEUTICS INC
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Stoke Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Stoke Therapeutics, Inc.
What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing?
Stoke Therapeutics (NasdaqGS:STOK) filed a shelf registration for a potential 2,000,000 common share offering reportedly tied to an Employee Stock Ownership Plan. The filing indicates possible future capital raising activity that could affect Stoke Therapeutics' capital structure and ownership mix. The ESOP related nature of the offering highlights employee equity participation as a factor in the company's compensation approach. To put this kind of equity move in context and see how other...
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement
Stoke Therapeutics stays a Buy as zorevunersen hits key Dravet milestones and STK-002 advances; strong cash runway to 2028. Click for more on STOK stock.
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
BEDFORD, Mass., August 05, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annu
Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Stoke Therapeutics, Inc.'s Q2 2026 earnings call
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target
Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.